DR HABEEBULLAH LIFE SCIENCES L DRHABEEB

DRHABEEB BSE
DRHABEEB
DR HABEEBULLAH LIFE SCIENCES L BSE
 
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E

DRHABEEB Stock Chart

Trade DRHABEEB with trusted brokers on TradingView Open account
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Health Technology
Industry: Biotechnology
Dr. Habeebullah Life Sciences Ltd. engages in the bio-pharma business in India and internationally. It offers DNA and RNA based tests for infectious diseases, oncology, endocrinology, transplantation typing, haematology, pharmacogenetics, and pre-natal and pre-implantation genetic diagnostics; and karyotype fluorescence in-situ hybridization analysis to detect targeted chromosome abnormalities. The firm is also involved in stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nanoformulation of cancer drugs, molecular genetics, and molecular virology, as well as focuses on the body organs of liver, pancreas, neural, cardiac, vascular, renal, and ortho. In addition, it engages in new drug discovery, including new molecular entity for wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular disease, cystinosis, and huntington's disease. Further, the company provides molecular prognosis and diagnostics services in the areas of cytogenetics, pharmacogenomics, pathology, radiology, hematology, bio chemistry, micro biology, and others. Additionally, it is involved in out-patient consultancy activities; pharmacy, diagnostics, and bio lab activities; research and development in bio-technology; and contract research organization related activities. It offers molecular diagnostics services to patients, private consultants, hospitals, and other healthcare institutions. The company was founded on January 25, 1996 and is headquartered in Hyderabad, India.